Intelligence · Clinical Development
Pipeline search results
Programs matching “treatment” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 270 pipeline programs matching "treatment" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
D-FR-10200-002
Ipsen
Treatment of Moderate to Severe Upper Facial Lines
1 trial -
D24-P003
Pari Pharma GmbH
Treatment-resistant depression
1 trial -
D822GC00001
AstraZeneca AB
Treatment Naïve Mantle Cell Lymphoma
1 trial -
DS-8201a
AstraZeneca AB
Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology
1 trial -
EDP-420 / Duration of Treatment - 3 days
ENANTA PHARMACEUTICALS INC
Community Acquired Pneumonia
1 trial -
ELACESTRANT
Fondazione Telethon ETS
Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)
1 trial -
ENCORAFENIB , CETUXIMAB
The George Institute
Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.
1 trial -
EORTC 2334-BTG
Ningbo Cancer Hospital
Recurrent Meningioma without local treatment options (Surgery or Radiotherapy)
1 trial -
ElechtraPlatinum
Istituto Gentili S.r.l.
relapsing vulvar carcinoma already subjected to multiple treatments
1 trial -
EnEPC-CLI-01
Biogen
Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.
1 trial -
EudraCT: 2008-004014-27
Lxo Ireland Designated Activity Company
Graft Versus Host Disease
1 trial -
F-FR-60000-023
Ipsen
Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors
1 trial -
Fibromun, Darleukin
Philogen S.p.A.
Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.
1 trial -
GH001-TRD-201
Elan Pharma International
Treatment-resistant depression (TRD)
1 trial -
GINECO- CE111b
Ningbo Cancer Hospital
Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.
1 trial -
Gemcitabine
BRIGHT MINDS BIOSCIENCES INC.
Treatment Refusal
1 trial -
Group A：Patients with PR or ctDNA positivity after salvage treatment
The First People's Hospital of Lianyungang
Diffuse Large B-cell Lymphoma(DLBCL)
1 trial -
IB 2021-01
The George Institute
Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.
1 trial -
IC 2019-05
The George Institute
Ocular conservative treatment for retinoblastoma
1 trial -
INCB 54707-208
Incyte
Treatment of patients with inadequately controlled moderate to severe asthma
1 trial -
IVERMECTIN
The George Institute
Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.
1 trial -
JNJ-73841937 for Patients with EGFR-mutant (L858…
Partner Therapeutics Limited
Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.
1 trial -
KALINOX 50%/50% for Treatment of suicidal ideation
Tour Hekla
Treatment of suicidal ideation
1 trial -
Liraglutide Pen Injector
BRIGHT MINDS BIOSCIENCES INC.
Opiate Substitution Treatment
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.